Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
RegulatorynegativeBHV-7000Negative
AI Analysis
Summary
Biohaven's BHV-7000 faces an FDA-imposed enrollment pause in pivotal epilepsy trials following prior efficacy failure in a depression study and recent FDA rejection of the company's spinocerebellar ataxia treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
FDA paused enrollment in pivotal trials for BHV-7000 epilepsy drug; BHV-7000 previously failed to show efficacy in midstage depression trial; FDA declined to approve spinocerebellar ataxia treatment in November 2025
Importance:8/10
Sentiment:
-0.90
regulatory setbackenrollment pausetrial failureFDA rejectionepilepsydepression
Related Companies
Read the original article
Published by BioSpace on September 10, 2026 2:04 PM